NCT07652892 Impact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective.
| NCT ID | NCT07652892 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Condition | Steatosis of Liver |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2026-05-26 |
| Primary Completion | 2027-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2026-05-26 with a primary completion date of 2027-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to determine the differences in the prevalence, characteristics and evolution of frailty between men and women diagnosed with MASLD, and to establish its relationship with clinical, functional, hormonal and social parameters.
Eligibility Criteria
Inclusion Criteria: * Patients will be included who are able to provide informed consent and actively participate in periodic assessments. Exclusion Criteria: * Risky alcohol consumption: \> 30 g/day in men and \> 20 g/day in women. AUDIT score: \> 7 points in men, \> 5 in women. * Other liver diseases (viral hepatitis, autoimmune hepatitis, etc.). * Advanced neurodegenerative diseases or severe psychiatric disorders. * Severe comorbidities or treatments that, in the researchers' judgment, may affect frailty and quality of life more than metabolic syndrome and liver disease.
Contact & Investigator
Eva Roman
PRINCIPAL INVESTIGATOR
Institut de Recerca IR Sant Pau
Frequently Asked Questions
Who can join the NCT07652892 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Steatosis of Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07652892 currently recruiting?
Yes, NCT07652892 is actively recruiting participants. Contact the research team at ERoman@santpau.cat for enrollment information.
Where is the NCT07652892 trial being conducted?
This trial is being conducted at Barcelona, Spain, Barcelona, Spain.
Who is sponsoring the NCT07652892 clinical trial?
NCT07652892 is sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. The principal investigator is Eva Roman at Institut de Recerca IR Sant Pau. The trial plans to enroll 140 participants.